Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda

The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024.Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a newly launched cardiovascular drug. The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion on increased demand f ...